[Clozapine and resistant schizophrenia].

Area of Science:

• Pharmacology
• Neuroscience

Context:

• Clozapine is an atypical antipsychotic drug.
• It is chemically and pharmacologically distinct from traditional neuroleptics.
• It exhibits moderate activity on dopaminergic pathways, blocking D1 and D2 receptors equally.

Purpose:

• To differentiate clozapine from conventional neuroleptics.
• To highlight its unique pharmacological profile and efficacy in treatment-resistant schizophrenia.
• To inform about its side-effect profile, particularly agranulocytosis.

Summary:

• Clozapine, a tricyclic dibenzodiazepine derivative, shows unique efficacy in treatment-resistant schizophrenia, improving both positive and negative symptoms.
• Unlike typical neuroleptics, it causes psychomotor inhibition without catalepsy and has a low incidence of extrapyramidal side-effects.
• Its distinct receptor binding profile includes adrenergic, histaminic, serotonergic, and muscarinic antagonism.
• A significant risk of agranulocytosis necessitates careful patient selection and regular blood monitoring.

Impact:

• Clozapine offers a vital therapeutic option for patients with schizophrenia refractory to other treatments.
• Understanding its distinct mechanism and side effects is crucial for safe and effective clinical use.
• The risk of agranulocytosis underscores the importance of pharmacovigilance and patient monitoring protocols.